Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × INDUSTRY × Non-Small Cell Lunch Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 410 Carcinoma, Non-Small-Cell Lung 375 Breast Neoplasms 292 Neoplasm Metastasis 197 Colorectal Neoplasms 178 Melanoma 176 Leukemia, Myeloid, Acute 166 Multiple Myeloma 148 Ovarian Neoplasms 143 Recurrence 141 Prostatic Neoplasms 141 Lymphoma, Non-Hodgkin 128 Lung Neoplasms 107 Lymphoma 104 Pancreatic Neoplasms 102 Leukemia, Lymphocytic, Chronic, B-Cell 97 Squamous Cell Carcinoma of Head and Neck 92 Carcinoma, Renal Cell 91 Leukemia 76 Stomach Neoplasms 75 Lymphoma, Large B-Cell, Diffuse 74 Carcinoma, Hepatocellular 74 Lymphoma, Follicular 72 Head and Neck Neoplasms 67 Triple Negative Breast Neoplasms 66 Glioblastoma 61 Urinary Bladder Neoplasms 60 Myelodysplastic Syndromes 60 Small Cell Lung Carcinoma 51 Brain Neoplasms 44

Interventions

Paclitaxel 1 NVP-BKM120 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01820325 2018-10-11

BASALT-2

Novartis

Phase 1 Terminated

Non-Small Cell Lunch Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡